Breaking News

Financial Report: Merck

February 1, 2013

Revenues down 5% in the quarter

4QRevenue: $11.7 billion (-5%)

4Q Earnings: $1.4 billion (-7%)

YTD Revenues: $47.3 billion (-2%)

YTD Earnings: $6.7 billion (+6%)

Comments: Pharmaceutical sales were down 6% to $10.1 billion, including a 1% percent negative impact due to foreign exchange. Singulair sales were down 67% to $480 million. Cozaar/Hyzaar sales were down 26% to $315 million. Januvia sales were $1.1 billion in the quarter, up 18%. Zetia sales were $676 million, up 6%. Remicade sales were up 8% to $549 million. Janumet sales were up 17% to $452 million. Gardasil sales were up 61% to $442 million. Merck Animal Health sales totaled $898 million for the quarter, up 3%. Consumer Care sales were $395 million, up 9%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks